

REMARKS

Applicants respectfully request reconsideration of the application.

CLAIMS STATUS

Applicants have cancelled claims 8-10 without prejudice or disclaimer. Applicants reserve a right to file one or more continuation applications directed to the subject matter of the cancelled claims.

Applicants have added new claim 11. Support for claim 11 may be found throughout the application as filed and, in particular, in original claim 1, previously presented claims 9 and 10, in examples 2, 3 and 4 which demonstrate the increase of the recalcification time obtained with the liposome destabilase complex, the immunostimulative and hypotensive actions, and the fibrinolytic and antithrombic activities of said complex and paragraphs [0003], [0008] and [0004].

Paragraph [0003]: *"It is known that atheromatous vascular diseases corresponding to narrowing of the arteries can be treated by expansion cuff techniques, techniques named angioplasties."* And *" ..., it is known to implant in the blood vessel in the area treated by angioplasty, an endoprosthesis, more frequently called a stent, ... "*

Paragraph [0008]: *"The invention is intended ... to obtain a composition with both anticoagulating and immunomodulating properties, capable of being associated with equipment such as stent, and in the form of liposomes so as to obtain an appropriate release of the substance"*.

Paragraph [0004]: *"... stents can be covered with therapeutically active substances, particularly intended to act in the implantation area"*.

No new matter has been added.

Claim 11 is the only pending claim.

CLAIM REJECTIONS UNDER 35 U.S.C. § 103

Claims 8-10 stand rejected as obvious over Bini (US 6,020,181) in view of Nikonov. Fundam. Clin. Pharmacol. 1999; 13(1): 102-56.

Applicants believe that the revised set of claims obviates the rejection.

NEW CLAIM 11

Applicants respectfully submit that new claim 11 is new and non obvious over Nikonov and Bini, taken alone or in combination.

New claim 11 relates to “a method for inducing fibrinolysis and thrombolysis, for increasing recalcification and immunostimulation, and for reducing blood pressure in the stent implantation area of a blood vessel treated by angioplasty”.

Nikonov et al. teach the anticoagulating activity of a liposome destabilase complex obtained from a leech extract. However, Nikonov et al. does not disclose nor suggest the increased immunostimulating properties of the the liposome destabilase complex, or reduced blood pressure obtained after the rat injection of the liposome destabilase complex.

Bini only suggests a method of inhibiting thrombus formation by a medical-related apparatus covered with a composition having fibrinolytic activity.

In sum, Bini in view of Nikonov does not suggest **a method comprising the implantation of a stent covered with a cladding consisting of the liposome destabilase complex disclosed in the current application for inducing fibrinolysis and thrombolysis, for increasing recalcification and immunostimulation, and for reducing blood pressure in the stent implantation area of a blood vessel treated by angioplasty.**

Finally, Applicants respectfully submit that as discussed in the specification the “*prior art does not describe any substances that are capable of forming a cladding for stents in the form of a liposome, and with anticoagulating and immunomodulating activities. Two separate medicines have to be administered to the patient according to prior art, namely an anticoagulating substance and an immunomodulating substance*”. See paragraph [0006].

CONCLUSION

Applicants believe that the present application is in condition for allowance. Favourable reconsideration of the application as amended is respectfully requested. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check or credit card payment form being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicants hereby petition for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date Aug. 20, 2007

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By Stephen B. Maebius

Stephen B. Maebius
Attorney for Applicants
Registration No. 35,264